Fairmount Funds Management LLC
Director; Director, 10% Owner · 6 filings · Latest: Mar 31, 2026
Apogee Therapeutics, Inc.
Cogent Biosciences, Inc.
Damora Therapeutics, Inc.
Galecto, Inc.
Zenas BioPharma, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
ZBIO | Fairmount Funds Management LLC | Director | Mar 31, 2026 | Purchase | $20.00 | 150,000 | $3.0M | 2,359,025 | |
COGT | Fairmount Healthcare Fund II L.P. | — | Mar 31, 2026 | Proposed Sale | $34.66 | 7,000,000 | $242.6M | — | |
COGT | Fairmount Funds Management LLC | Director | Mar 31, 2026 | Sale | $34.66 | 7,000,000 | $242.6M | 5,503,418 | |
GLTO | Fairmount Funds Management LLC | Director, 10% Owner | Feb 9, 2026 | Option Exercise | $0.00 | 8,713,000 | — | 2,904,000 | |
COGT | Fairmount Funds Management LLC | Director | Jan 22, 2026 | Sale | $36.40 | 3,500,000 | $127.4M | 5,503,418 | |
APGE | Fairmount Funds Management LLC | Director | Jan 22, 2026 | Sale | $76.30 | 1,750,000 | $133.5M | 298,647 | |
COGT | Fairmount Healthcare Fund II L.P. | — | Jan 22, 2026 | Proposed Sale | $36.40 | 3,500,000 | $127.4M | — | |
APGE | Fairmount Healthcare Fund II L.P. | — | Jan 22, 2026 | Proposed Sale | $76.30 | 1,750,000 | $133.5M | — |